Drug Safety

, Volume 13, Issue 6, pp 338–342 | Cite as

A Reappraisal of Quinolone Tolerability

The Experience of their Musculoskeletal Adverse Effects
  • Gilles Hayem
  • Claude Carbon
Leading Article

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Williams JD. Quo vadis with bacterial resistance? Drugs 1995; 49 Suppl. 2: 1–9PubMedCrossRefGoogle Scholar
  2. 2.
    Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics: past, present and future. Drug Saf 1995 Dec; 13(6): 343–58PubMedCrossRefGoogle Scholar
  3. 3.
    Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis 1994; 18: 946–50PubMedCrossRefGoogle Scholar
  4. 4.
    Rubinstein E. Tolerance of sparfloxacin. Sparfloxacin Symposium. Rhone Poulenc Rorer; 1995 Jun 24–25; SevilleGoogle Scholar
  5. 5.
    Huston KA. Achilles tendinitis and tendon rupture due to fluoroquinolone antibiotics. N Engl J Med 1994; 331: 748PubMedCrossRefGoogle Scholar
  6. 6.
    Lee WT, Collins JF. Ciprofloxacin associated bilateral tendon rupture. Aust NZ J Med 1992; 22: 500Google Scholar
  7. 7.
    MacEwan SR, Davey PG. Ciprofloxacin and tenosynovitis. Lancet 1988; ii: 900CrossRefGoogle Scholar
  8. 8.
    Ribard P, Audisio F, Kahn MF, et al. Seven Achilles tendonitis including 3 complicated by rupture during fluoroquinolone therapy. J Rheumatol 1992; 19: 1479–81PubMedGoogle Scholar
  9. 9.
    Szarfman A, Chen M, Blum MD. More on fluoroquinolone antibiotics and tendon rupture [letter]. N Engl J Med 1995; 332: 193PubMedCrossRefGoogle Scholar
  10. 10.
    Schaad U, Salam MA, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy Commission. Pediatr Infect Dis J 1995; 14: 1–9PubMedCrossRefGoogle Scholar
  11. 11.
    Chysky V, Kapila K, Jullman G, et al. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use: emphasis on joint evaluation. Infection 1991; 19: 289–96PubMedCrossRefGoogle Scholar
  12. 12.
    Pradhan KM, Arora NK, Jena A, et al. Safety of ciprofloxacin therapy in children: magnetic resonance images, body fluid levels of fluoride and linear growth. Acta Paediatr 1995; 84: 555–60PubMedCrossRefGoogle Scholar
  13. 13.
    Schaad UB, Sander E, Wedgwood J, et al. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients. Pediatr Infect Dis J 1992; 11: 1047–9PubMedCrossRefGoogle Scholar
  14. 14.
    Bouissou H, Caujolle D, Caujolle F, et al. Toxicologie experimentale. Tissus cartilagineux et acide nalidixique. C R Acad Sci Hebd Seances Acad Sci D 1978; 286: 1743–6PubMedGoogle Scholar
  15. 15.
    Gough A, Barsoum NJ, Mitchell L, et al. Juvenile canine druginduced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol 1979; 51: 177–87PubMedCrossRefGoogle Scholar
  16. 16.
    Ingham B, Brentnall DW, Dale EA, et al. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids. Toxicol Lett 1977; 1: 21–6CrossRefGoogle Scholar
  17. 17.
    McDonald DF, Short HB. Usefulness of nalidixic acid in treatment of urinary infection. Antimicrob Agents Chemother 1964; 4: 628–31Google Scholar
  18. 18.
    Ribard P, Kahn MF. Rheumatological side-effects of quinolones. In: Kahn MF, editor. Baillière’s clinical rheumatology: drug-induced rheumatic diseases. London: Baillière Tindall, 1991: 175–91Google Scholar
  19. 19.
    Chevalier X, Albengres E, Voisin MC, et al. A case of destructive polyarthropathy in a 17-year-old youth following pefloxacin treatment. Drug Saf 1992; 7: 310–4PubMedCrossRefGoogle Scholar
  20. 20.
    Pertuiset E, Lenoir G, Jehanne M, et al. Tolérance articulaire de la péfloxacine et de l’ofloxacine chez les enfants et adolescents atteints de mucoviscidose. Rev Rhum Mal Osteoartic 1989; 56: 735–40PubMedGoogle Scholar
  21. 21.
    Schaad UB, Stoupis C, Wedgwood J, et al. et al. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J 1991; 10: 723–9PubMedGoogle Scholar
  22. 22.
    Tatsumi H, Senda H, Yatera S, et al. Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals. J Toxicol Sci 1978; 3: 357–67PubMedCrossRefGoogle Scholar
  23. 23.
    Burkhardt JE, Hill MA, Turek JJ, et al. Ultrastructural changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol 1992; 29: 230–8PubMedCrossRefGoogle Scholar
  24. 24.
    Stahlmann R, Merker HJ, Hinz N, et al. Ofloxacin in juvenile non-human primates and rats. Arthropathia and drug plasma concentrations. Arch Toxicol 1990; 64: 193–204PubMedCrossRefGoogle Scholar
  25. 25.
    Burkhardt JE, Hill MA, Carlton WW, et al. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol 1990; 27: 162–70PubMedCrossRefGoogle Scholar
  26. 26.
    Machida M, Kusajima H, Aijima H, et al. Toxokinetic study of norfloxacin-induced arthropathy in juvenile animals. Toxicol Appl Pharmacol 1990; 105: 403–12PubMedCrossRefGoogle Scholar
  27. 27.
    Hayem G, Petit PX, Levacher M, et al. Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents. Antimicrob Agents Chemother 1994; 38: 243–7PubMedCrossRefGoogle Scholar
  28. 28.
    Thuong-Guyot M, Domarle O, Pocidalo JJ, et al. Effects of fluoroquinolones on cultured articular chondrocytes. Flow cytometric analysis of free radical production. J Pharmacol Exp Ther 1994; 271: 1544–9PubMedGoogle Scholar
  29. 29.
    Bendele AM, Hulman JF, Harvey AK, et al. Passive role of articular chondrocytes in quinolone-induced arthropathy in guinea pigs. Toxicol Pathol 1990; 18: 304–12PubMedCrossRefGoogle Scholar
  30. 30.
    Stahlmann R, Förster C, Shakibaei M, et al. Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical to quinolone induced arthropathy. Antimicrob Agents Chemother 1995; 39: 2013–8PubMedCrossRefGoogle Scholar
  31. 31.
    Perrot S, Ziza JM, De Bourran-Cauet G, et al. Nouvelle complication liée aux quinolones: la rupture du tendon d’Achille. Presse Med 1991; 20: 1234PubMedGoogle Scholar
  32. 32.
    Kato M, Takeda S, Kashida Y, et al. Histological examination of Achilles tendon lesions induced by quinolone antibacterial agents in juvenile rats. Toxicol Path 1995; 23: 385–92CrossRefGoogle Scholar
  33. 33.
    Bailey RR, Kirk JA, Peddie B A. Norfloxacin induced rheumatic disease. NZ Med J 1983; 96: 590Google Scholar
  34. 34.
    Bailey RR, Peddie BA. Enoxacin for the treatment of urinary tract infection. NZ Med J 1985; 98: 286–8Google Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Gilles Hayem
    • 1
    • 3
  • Claude Carbon
    • 2
    • 3
  1. 1.Clinique de RhumatologieCHU Bichat-Claude BernardParisFrance
  2. 2.Service de Médecine InterneCHU Bichat-Claude BernardParisFrance
  3. 3.INSERM U 13CHU Bichat-Claude BernardParisFrance

Personalised recommendations